BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24710931)

  • 1. miR-21 targets Fas ligand-mediated apoptosis in breast cancer cell line MCF-7.
    Wu MF; Yang J; Xiang T; Shi YY; Liu LJ
    J Huazhong Univ Sci Technolog Med Sci; 2014 Apr; 34(2):190-194. PubMed ID: 24710931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival.
    Xu G; Zhang J
    J Cancer Res Clin Oncol; 2008 Oct; 134(10):1043-9. PubMed ID: 18461366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression.
    Prado-Garcia H; Aguilar-Cazares D; Meneses-Flores M; Morales-Fuentes J; Lopez-Gonzalez JS
    Cancer Immunol Immunother; 2008 Mar; 57(3):325-36. PubMed ID: 17668204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway.
    Liu WH; Chang LS
    Int J Biochem Cell Biol; 2011 Dec; 43(12):1708-19. PubMed ID: 21854868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of FasL expression in tumor cells and preventing tumor necrosis factor-induced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells.
    Zhang J; Xu G
    Cancer Genet Cytogenet; 2007 Dec; 179(2):112-7. PubMed ID: 18036397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.
    Ragnarsson GB; Mikaelsdottir EK; Vidarsson H; Jónasson JG; Olafsdóttir K; Kristjánsdóttir K; Kjartansson J; Ogmundsdóttir HM; Rafnar T
    Br J Cancer; 2000 Dec; 83(12):1715-21. PubMed ID: 11104571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of direct target genes of miR-7, miR-9, miR-96, and miR-182 in the human breast cancer cell lines MCF-7 and MDA-MB-231.
    Moazzeni H; Najafi A; Khani M
    Mol Cell Probes; 2017 Aug; 34():45-52. PubMed ID: 28546132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of miR-98 in myocarditis and its influence on transcription of the FAS/FASL gene pair.
    Zhang BY; Zhao Z; Jin Z
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
    Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
    Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
    Kim R; Emi M; Tanabe K; Uchida Y; Toge T
    Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-125a-5p inhibits the proliferation and invasion of breast cancer cells and induces apoptosis by targeting GAB2.
    Wang LB; Feng L; He J; Liu B; Sun JG
    Math Biosci Eng; 2019 Jul; 16(6):6923-6933. PubMed ID: 31698596
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of FasL expression in oral squamous cell cancer.
    Fang L; Sun L; Hu FF; Chen QE
    Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of Fas/FasL pathway blocking on apoptosis and stemness within breast cancer tumor microenvironment (preclinical study).
    Abou Shousha S; Baheeg S; Ghoneim H; Zoheir M; Hemida M; Shahine Y
    Breast Dis; 2023; 42(1):163-176. PubMed ID: 37334575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between up-regulation of Fas ligand expression and apoptosis of tumor-infiltrating lymphocytes in human breast cancer.
    Cheng B
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(5):573-5. PubMed ID: 17219972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-21 down-regulation suppresses cell growth, invasion and induces cell apoptosis by targeting FASL, TIMP3, and RECK genes in esophageal carcinoma.
    Wang N; Zhang CQ; He JH; Duan XF; Wang YY; Ji X; Zang WQ; Li M; Ma YY; Wang T; Zhao GQ
    Dig Dis Sci; 2013 Jul; 58(7):1863-70. PubMed ID: 23504349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis.
    Zhang L; Wang L; Dong D; Wang Z; Ji W; Yu M; Zhang F; Niu R; Zhou Y
    Cell Prolif; 2019 Jan; 52(1):e12527. PubMed ID: 30334298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.
    Zhang W; Ding EX; Wang Q; Zhu DQ; He J; Li YL; Wang YH
    World J Gastroenterol; 2005 Jun; 11(23):3632-5. PubMed ID: 15962391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.
    O'Connell J; Bennett MW; O'Sullivan GC; O'Callaghan J; Collins JK; Shanahan F
    Clin Diagn Lab Immunol; 1999 Jul; 6(4):457-63. PubMed ID: 10391843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA (lncRNA) MAGI2-AS3 inhibits breast cancer cell growth by targeting the Fas/FasL signalling pathway.
    Yang Y; Yang H; Xu M; Zhang H; Sun M; Mu P; Dong T; Du S; Liu K
    Hum Cell; 2018 Jul; 31(3):232-241. PubMed ID: 29679339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fas signaling induces stemness properties in colorectal cancer by regulation of Bmi1.
    Chen J; Wang Y; Zhuo L; Liu Z; Liu T; Li W; Cai Y; Zheng H
    Mol Carcinog; 2017 Oct; 56(10):2267-2278. PubMed ID: 28543447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.